Global Markets Direct’s, 'Injury - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Injury. Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Injury. - A review of the Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Injury. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Injury pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Injury - Pipeline Review, H2 2013 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Injury Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Injury 7 Injury Therapeutics under Development by Companies 9 Injury Therapeutics under Investigation by Universities/Institutes 10 Discovery and Pre-Clinical Stage Products 11 Comparative Analysis 11 Injury Therapeutics - Products under Development by Companies 12 Injury Therapeutics - Products under Investigation by Universities/Institutes 13 Companies Involved in Injury Therapeutics Development 14 Ascent Therapeutics 14 Atox Bio Inc. 15 Cornerstone Therapeutics Inc. 16 Injury - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 HMGB1 Monoclonal Antibody - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 AB-103 - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 Platelet Receptors Inhibitor - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 GM1-Targeted Linoleate-Containing TLR2 ligand - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 ATI-2341 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 Human sRAGE Protein - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 Injury Therapeutics - Drug Profile Updates 31 Injury Therapeutics - Dormant Products 33 Injury - Product Development Milestones 34 Featured News and Press Releases 34 Oct 03, 2012: Oxygen Biotherapeutics Signs Cooperative Research And Development Agreement With US Navy To Investigate Oxycyte For Complex Infected Wounds And Related Injuries 34 Jul 30, 2012: Stem Cell Therapy May Offer New Hope For Defects And Injuries To Head, Mouth 34 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 37 Disclaimer 37
List of Tables
Number of Products Under Development for Injury, H2 2013 7 Products under Development for Injury - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Number of Products under Investigation by Universities/Institutes, H2 2013 10 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11 Products under Development by Companies, H2 2013 12 Products under Investigation by Universities/Institutes, H2 2013 13 Ascent Therapeutics, H2 2013 14 Atox Bio Inc., H2 2013 15 Cornerstone Therapeutics Inc., H2 2013 16 Assessment by Monotherapy Products, H2 2013 17 Assessment by Stage and Route of Administration, H2 2013 19 Assessment by Stage and Molecule Type, H2 2013 21 Injury Therapeutics - Drug Profile Updates 31 Injury Therapeutics - Dormant Products 33
List of Figures
Number of Products under Development for Injury, H2 2013 7 Products under Development for Injury - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Products under Investigation by Universities/Institutes, H2 2013 10 Discovery and Pre-Clinical Stage Products, H2 2013 11 Assessment by Monotherapy Products, H2 2013 17 Assessment by Route of Administration, H2 2013 18 Assessment by Stage and Route of Administration, H2 2013 19 Assessment by Molecule Type, H2 2013 20 Assessment by Stage and Molecule Type, H2 2013 21